2.79

1.09% 0.03

Black Diamond Therapeutics Inc (BDTX)

Overview News Price History Option Chain Financials Discussions Forecast

Black Diamond Therapeutics Inc stock is traded at $2.79, with a volume of 1.12M. It is up +1.09% in the last 24 hours and down -42.71% over the past month. Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.

Previous Close:

$2.76

Open:

$2.79

24h Volume:

1.12M

Relative Volume:

0.92

Market Cap:

$158.96M

Revenue:

Net Income/Loss:

$-82.44M

P/E Ratio:

-1.484

EPS:

-1.88

Net Cash Flow:

$-66.75M

1W Performance:

+4.49%

1M Performance:

-42.71%

6M Performance:

+14.81%

1Y Performance:

+11.60%

1-Day Range:

$2.72

$2.84

1-Week Range:

$2.605

$2.84

52-Week Range:

$1.195

$4.94

Black Diamond Therapeutics Inc Stock (BDTX) Company Profile

Name

Black Diamond Therapeutics Inc

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

617-417-5868

Address

ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA

Employee

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

BDTX's Discussions on Twitter

Compare BDTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BDTX Black Diamond Therapeutics Inc	2.79	157.25M	0	-82.44M	-66.75M	-1.88
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-03-25	Downgrade	Guggenheim	Buy → Neutral
Nov-18-25	Resumed	Piper Sandler	Overweight
Oct-16-25	Resumed	Stifel	Buy
Sep-04-25	Initiated	Guggenheim	Buy
Jul-01-25	Resumed	Raymond James	Outperform
Jul-31-24	Initiated	Raymond James	Outperform
Jul-14-23	Initiated	Piper Sandler	Overweight
Jun-30-23	Upgrade	Stifel	Hold → Buy
Jun-28-23	Upgrade	H.C. Wainwright	Neutral → Buy
Jun-27-23	Upgrade	Wedbush	Neutral → Outperform
Mar-29-22	Downgrade	Wedbush	Outperform → Neutral
Mar-22-22	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-30-21	Initiated	Stifel	Hold
Jan-07-21	Initiated	Wedbush	Outperform
Nov-24-20	Initiated	Berenberg	Buy
May-04-20	Initiated	H.C. Wainwright	Buy
Feb-24-20	Initiated	Canaccord Genuity	Buy
Feb-24-20	Initiated	Cowen	Outperform
Feb-24-20	Initiated	JP Morgan	Overweight
Feb-24-20	Initiated	Jefferies	Buy

View All

Black Diamond Therapeutics Inc Stock (BDTX) Latest News

Dec 10, 2025

Black Diamond Therapeutics (BDTX) – Analysts’ Weekly Ratings Updates - Defense World

Dec 10, 2025

Dec 09, 2025

A strong week for data readouts: Clinical Report - BioCentury

Dec 09, 2025

Dec 08, 2025

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Dec 08, 2025

Dec 05, 2025

Can Black Diamond Therapeutics (BDTX) Turn Silevertinib’s Dual-Cancer Ambition Into a Cohesive Strategy? - Yahoo Finance

Dec 05, 2025

Down 30.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX) - sharewise.com

Dec 05, 2025

Can Black Diamond Therapeutics Inc. stock continue upward trendGap Down & Long-Term Investment Growth Plans - Newser

Dec 05, 2025

Will Black Diamond Therapeutics Inc. stock attract more institutional investorsInsider Selling & Technical Pattern Based Buy Signals - Newser

Dec 05, 2025

Dec 04, 2025

Black Diamond Therapeutics (NASDAQ:BDTX) Stock Rating Lowered by Guggenheim - MarketBeat

Dec 04, 2025

Stifel reiterates Buy rating on Black Diamond Therapeutics stock at $8 - Investing.com Australia

Dec 04, 2025

Analyst Downgrades BDTX to Neutral from Buy | BDTX Stock News - GuruFocus

Dec 04, 2025

This PayPal Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Benzinga

Dec 04, 2025

How Black Diamond Therapeutics Inc. stock reacts to oil pricesBond Market & Consistent Profit Trade Alerts - Newser

Dec 04, 2025

Dec 03, 2025

Black Diamond's Lung Cancer Drug Shows 60% Response Rate In Phase 2 Data - Sahm

Dec 03, 2025

Are Smart Investors Making the Right Decision? Black Diamond Therapeutics Inc (BDTX) - Setenews

Dec 03, 2025

US Stocks Mixed; Dollar Tree Posts Upbeat Earnings - Benzinga

Dec 03, 2025

Black Diamond Therapeutics announces preliminary Phase 2 data for Silevertinib in 1L NSCLC - marketscreener.com

Dec 03, 2025

Black Diamond Therapeutics (BDTX) Reveals Promising Phase 2 Tria - GuruFocus

Dec 03, 2025

Black Diamond Therapeutics Announces Preliminary Phase 2 - GlobeNewswire

Dec 03, 2025

Black Diamond to present Phase 2 silevertinib trial results By Investing.com - Investing.com Canada

Dec 03, 2025

Dec 02, 2025

Black Diamond to present Phase 2 silevertinib trial results - Investing.com India

Dec 02, 2025

Black Diamond Therapeutics to Host Webcast on Phase 2 Clinical Trial Results of Silevertinib on December 3, 2025 - Quiver Quantitative

Dec 02, 2025

Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update - The Manila Times

Dec 02, 2025

Black Diamond Therapeutics to Host Webcast Presentation - GlobeNewswire

Dec 02, 2025